novo nordisk goodrx - Search News

News

Novo Nordisk, GoodRX, CVS

Barron's on MSN · 17h

Novo Nordisk Adds Ozempic to Direct-to-Consumer Offerings, at $499 Per Month. Why GoodRx Stock Spikes.

Shares of GoodRx were spiking 35% on Monday. The announcement followed news from Novo Nordisk that the Food and Drug Administration had approved Wegovy for treatment of a serious form of liver disease. Shares of the Danish drugmaker were rising 4.9% in U.S. trading.

Reuters on MSN · 14h

Novo Nordisk offers Ozempic at $499 per month to eligible US cash-paying customers

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S. via its own pharmacy, a tie-up with telehealth service GoodRx and other platforms.

Invezz on MSN · 12h

Is Novo Nordisk deal the much-needed catalyst for Goodrx stock?

Goodrx Holdings Inc (NASDAQ: GDRX) closed roughly 50% higher on August 18 after Bagsværd-headquartered Novo Nordisk (NYSE: NVO) announced a GLP-1 partnership with the healthcare platform. According to the companies’ joint press release today,

11hon MSN

US patients can now get Ozempic for half price if they can pay cash

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...

14h

GoodRx: After A 30% Surge On The Novo News, Is The Story Just Beginning?

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...

15hon MSN

Novo Nordisk to sell weight-loss drug for $499 to eligible customers

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results